CD38 and lymphoma: In vitro binding of nanobody JK36AF680 to daratumumab-pretreated cells was assessed using five human (LP-1, U266, RPMI-8226, CA46, Daudi) lymphoma cell lines, and one murine lymphoma cell line transfected with human CD38 (YAC-1 CD38+) (Figure 3A).